Physician profile
Leonid Vorobyev
NPI 1245259431
$4,505.11
in general payments reported to CMS, 2019-2025
17 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,372 · 2020: $395 · 2021: $300 · 2022: $118 · 2023: $327 · 2024: $561 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295 · Education: $25.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.12 |
| Education | $25.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,162.10 | 2019-2025 | Rexulti, Nuedexta |
| Allergan, INC. | $421.82 | 2019-2020 | |
| Axsome Therapeutics, INC. | $365.25 | 2025 | Auvelity |
| Alkermes, INC. | $282.13 | 2025 | Lybalvi |
| Avanir Pharmaceuticals, INC. | $243.17 | 2019 | |
| Lundbeck LLC | $203.07 | 2019 | |
| Vanda Pharmaceuticals INC. | $184.13 | 2025 | Fanapt |
| Biohaven Pharmaceuticals, INC. | $124.89 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $119.65 | 2020 | |
| Indivior INC. | $97.01 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.63 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $54.77 | 2019-2025 | Trintellix |
| Abbvie INC. | $50.47 | 2021 | |
| Sunovion Pharmaceuticals INC. | $48.25 | 2019 | |
| Shire North American Group INC | $42.55 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24.16 | 2025 | Spravato |
| Bausch Health US, LLC | $19.06 | 2025 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonid Vorobyev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.